About Exsure
Exsure is a company based in Bhubaneswar (India) founded in 2021 by Swastika Paul and Abhishek Dutta. Exsure has raised $346.88 thousand across 1 funding round from investors including Unicorn India Ventures. The company has 1 employees as of March 26, 2024. Exsure offers products and services including EXOSURE, LEUCOSURE, and DENDROSURE. Exsure operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Bhubaneswar, India
- Employees 1 as on 26 Mar, 2024
- Founders Swastika Paul, Abhishek Dutta
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Exsure Private Limited
- Date of Incorporation 18 Nov, 2021
- Jurisdiction Bhubaneswar, Orissa, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$346.88 K (USD)
in 1 rounds
-
Latest Funding Round
$346.88 K (USD), Seed
Jan 22, 2025
- Investors
-
Employee Count
1
as on Mar 26, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Exsure
Exsure offers a comprehensive portfolio of products and services, including EXOSURE, LEUCOSURE, and DENDROSURE.
Reagent for isolating exosomes from blood and cell-culture.
Lymphocyte separation reagent for blood samples.
Medium to convert monocytes into mature dendritic cells.
Funding Insights of Exsure
Exsure has successfully raised a total of $346.88K through 1 strategic funding round. The most recent funding activity was a Seed round of $346.88 thousand completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $346,878
-
First Round
First Round
(22 Jan 2025)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Seed - Exsure | Valuation | Unicorn India Ventures |
|
Investors in Exsure
Exsure has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Unicorn India Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm offering seed funding and support to startups in technology and innovation sectors.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Exsure
Financial Statements - Exsure
Exsure Comparisons
Competitors of Exsure
Exsure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
Latest news on Exsure
Frequently Asked Questions about Exsure
Exsure was founded in 2021 and raised its 1st funding round 4 years after it was founded.
Exsure is headquartered in Bhubaneswar, India. It is registered at Bhubaneswar, Odisha, India.
Abhishek Dutta is the current CEO of Exsure. They have also founded this company.
Exsure is a funded company, having raised a total of $346.88K across 1 funding round to date. The company's 1st funding round was a Seed of $346.88K, raised on Jan 22, 2025.
As of Mar 26, 2024, the latest employee count at Exsure is 1.
Exsure was founded in 2021 and is based in Bhubaneswar, India. Operations are centered in the biotechnology sector, where an exosome-based platform for chemotherapeutic drug delivery is being developed. Anti-cancer drugs are targeted precisely to tumor and relapse-causing cells through this technology, minimizing impact on healthy cells. The focus remains on advancing nano-scale solutions for oncology applications.
Exsure's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Exsure offers EXOSURE, LEUCOSURE, and DENDROSURE.
Exsure has 1 investor. Key investors include Unicorn India Ventures.